Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. (ARDS) Revenue
Annual & quarterly revenue history · segment & region breakdown
ARDS · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAridis Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.02B, an increase of 0.00% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | -$0.00B | -2.15% |
| 2019-12-31 | $0.00B | -$0.00B | -62.93% |
| 2018-12-31 | $0.00B | +$0.00B | +220.58% |
| 2017-12-31 | $0.00B | -$0.00B | -62.10% |
| 2016-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Aridis Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Aridis Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Aridis Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ARDS revenue · 4 questionsARDS's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 0.00% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Aridis Pharmaceuticals, Inc. SEC filings · GAAP · Aridis Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026